Stocks Health care APUS

NYSE · Health care

Apimeds Pharmaceuticals US, Inc. (APUS)

It posted a net loss of $58.2M. In fiscal 2025 capital spending exceeded operating cash flow by $9M. At June 30, 2026 it held $278.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Apimeds Pharmaceuticals US, Inc. does

Apimeds Pharmaceuticals US, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker APUS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Apimeds Pharmaceuticals US, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 23, 2026
   Shareholder rights changed 8-K
2. September 11, 2026
   Executive or director change 8-K
3. August 21, 2026
   Material agreement 8-K
4. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$11.77 versus -$2.57.
5. August 6, 2026
   Other event 8-K
6. July 13, 2026
   Other event 8-K
7. May 26, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$2.26 versus -$0.05.
8. May 15, 2026
   Late quarterly report notice NT 10-Q
9. May 7, 2026
   Activist stake changed SCHEDULE 13D/A
10. May 5, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 21, 2025. Insider transactions on SEC

Who owns APUS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about APUS

What does Apimeds Pharmaceuticals US, Inc. do?

Apimeds Pharmaceuticals US, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker APUS.

Is Apimeds Pharmaceuticals US, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $58.2M.

When did Apimeds Pharmaceuticals US, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder rights changed from September 23, 2026.

Similar companies

Compare APUS with

Compare APUS with any company

Follow APUS

Get an email when Apimeds Pharmaceuticals US, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow APUS: get an email when it files

Where the numbers come from

Financial figures are the values Apimeds Pharmaceuticals US, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.